Should COVID-19 be branded to viral thrombotic fever?

dc.creatorCosta-Filho, Rubens Carmo
dc.creatorCastro-Faria Neto, Hugo Caire
dc.creatorMengel, José
dc.creatorPelajo-Machado, Marcelo
dc.creatorMartins, Marco Aurélio
dc.creatorLeite, Érica Távora
dc.creatorMendonça-Filho, Hugo Tannus
dc.creatorSouza, Tatiana de Arruda Campos Brasil de
dc.creatorBentacor, Gonzalo Bello
dc.creatorLeite, José Paulo Gagliardi
dc.date2021-06-16T19:01:30Z
dc.date2021-06-16T19:01:30Z
dc.date2021
dc.date.accessioned2023-09-26T20:37:32Z
dc.date.available2023-09-26T20:37:32Z
dc.identifierCOSTA-FILHO, Rubens Carmo et al. Should COVID-19 be branded to viral thrombotic fever? Mem Inst. Oswaldo Cruz, n. 116, p. 1–8, 2021.
dc.identifier1678-8060
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/47732
dc.identifier10.1590/0074-02760200552
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8860824
dc.descriptionCoronaviruses can cause a diverse array of clinical manifestations, from fever with symptoms of the common cold to highly lethal severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS). SARS-CoV-2, the coronavirus discovered in Hubei province, China, at the end of 2019, became known worldwide for causing coronavirus disease 2019 (COVID-19). Over one year’s time period, the scientific community has produced a large bulk of knowledge about this disease and countless reports about its immune-pathological aspects. This knowledge, including data obtained in postmortem studies, points unequivocally to a hypercoagulability state. However, the name COVID-19 tells us very little about the true meaning of the disease. Our proposal is more comprehensive; it intends to frame COVID-19 in more clinical terminology, making an analogy to viral haemorrhagic fever (VHF). Thus, we found irrefutable evidence in the current literature that COVID-19 is the first viral disease that can be branded as a viral thrombotic fever. This manuscript points out that SARS-CoV-2 goes far beyond pneumonia or SARS. COVID-19 infections promote remarkable interactions among the endothelium, coagulation, and immune response, building up a background capable of promoting a “thrombotic storm,” much more than a “cytokine storm.” The importance of a viral protease called main protease (Mpro) is highlighted as a critical component for its replication in the host cell. A deeper analysis of this protease and its importance on the coagulation system is also discussed for the first time, mainly because of its similarity with the thrombin and factor Xa molecules, as recently pointed out by structural comparison crystallographic structures.
dc.formatapplication/pdf
dc.languagepor
dc.publisherFundação Oswaldo Cruz. Instituto Oswaldo Cruz
dc.rightsopen access
dc.subjectEndothelium
dc.subjectSARS CoV 2 Infection
dc.subjectCoronavirus 3C Proteases
dc.subjectInflammation
dc.subjectBlood Coagulation
dc.subjectThrombosis
dc.subjectThrombelastography
dc.subjectEndotelio
dc.subjectProteasas 3C de Coronavirus
dc.subjectInflamación
dc.subjectCoagulación Sanguínea
dc.subjectTrombosis
dc.subjectTromboelastografía
dc.subjectEndothélium
dc.subjectInflammation
dc.subjectCoagulation sanguine
dc.subjectThrombose
dc.subjectThromboélastographie
dc.subjectEndotélio
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.subjectProteína Mpro de Coronavírus
dc.subjectInflamação
dc.subjectCoagulação Sanguínea
dc.subjectTrombose
dc.subjectTromboelastografia
dc.titleShould COVID-19 be branded to viral thrombotic fever?
dc.typeArticle


Este ítem pertenece a la siguiente institución